Is Buying Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Here Good Idea?

October 2, 2018 - By whatsonthorold

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Logo

Investors sentiment decreased to 1 in 2018 Q2. Its down 0.50, from 1.5 in 2018Q1. It is negative, as 7 investors sold Actinium Pharmaceuticals, Inc. shares while 6 reduced holdings. 9 funds opened positions while 4 raised stakes. 6.70 million shares or 63.68% less from 18.45 million shares in 2018Q1 were reported.
Vanguard Gru Inc, Pennsylvania-based fund reported 2.42M shares. Savings Bank Of New York Mellon stated it has 48,402 shares or 0% of all its holdings. Malaga Cove Cap has 60,000 shares. Intrust Comml Bank Na holds 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) or 20,000 shares. Deutsche State Bank Ag reported 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Hartford Mgmt invested in 0% or 18,000 shares. Barclays Public Ltd Co has invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Sio Mgmt Limited Liability Com holds 0.31% or 872,406 shares. Geode Cap Management Lc owns 312,355 shares. Da Davidson Co invested 0% in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Oppenheimer & Inc owns 0% invested in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) for 73,552 shares. Sns Grp Inc Ltd Liability Co reported 26,000 shares. National Bank & Trust Of America De has invested 0% of its portfolio in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM). Bridgeway Cap reported 172,300 shares stake. Northern Tru Corporation accumulated 106,388 shares.

The stock of Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) registered an increase of 5.24% in short interest. ATNM’s total short interest was 3.81M shares in October as published by FINRA. Its up 5.24% from 3.62M shares, reported previously. With 619,100 shares average volume, it will take short sellers 6 days to cover their ATNM’s short positions.

The stock increased 2.29% or $0.017 during the last trading session, reaching $0.759. About 736,253 shares traded. Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) has risen 4.92% since October 2, 2017 and is uptrending. It has underperformed by 10.70% the S&P500.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The company has market cap of $83.86 million. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. It currently has negative earnings. The Company’s lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant.

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News